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Abstract
Background
Ghana started its national programme to eliminate lymphatic filariasis (LF) in 2000, with
mass drug administration (MDA) with ivermectin and albendazole as main strategy. We
review the progress towards elimination that was made by 2016 for all endemic districts
of Ghana and analyze microfilaria (mf) prevalence from sentinel and spot-check sites in
endemic districts.
Methods
We reviewed district level data on the history of MDA and outcomes of transmission assess-
ment surveys (TAS). We further collated and analyzed mf prevalence data from sentinel
and spot-check sites.
Results
MDA was initiated in 2001–2006 in all 98 endemic districts; by the end of 2016, 81 had
stopped MDA after passing TAS and after an average of 11 rounds of treatment (range
8–14 rounds). The median reported coverage for the communities was 77–80%. Mf preva-
lence survey data were available for 430 communities from 78/98 endemic districts. Base-
line mf prevalence data were available for 53 communities, with an average mf prevalence
of 8.7% (0–45.7%). Repeated measurements were available for 78 communities, showing a
steep decrease in mean mf prevalence in the first few years of MDA, followed by a gradual
further decline. In the 2013 and 2014 surveys, 7 and 10 communities respectively were
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identified with mf prevalence still above 1% (maximum 5.6%). Fifteen of the communities
above threshold are all within districts where MDA was still ongoing by 2016.
Conclusions
The MDA programme of the Ghana Health Services has reduced mf prevalence in sentinel
sites below the 1% threshold in 81/98 endemic districts in Ghana, yet 15 communities within
13 districts (MDA ongoing by 2016) had higher prevalence than this threshold during the sur-
veys in 2013 and 2014. These districts may need to intensify interventions to achieve the
WHO 2020 target.
Author summary
Lymphatic filariasis (LF) control in Ghana has relied on ivermectin and albendazole since
the year 2000 when the Ghana Filariasis Elimination Programme started. We analyzed
trends in microfilaraemia prevalence during MDA, reported coverage, and transmission
assessment survey using data obtained from the Ghana Health Services (GHS). The
median reported treatment coverage varied between 77–80% over the years. Our results
show that the treatment in Ghana made a significant impact in reducing infections <1%
in majority of sentinel sites in endemic districts (81/98) by 2016. In the remaining 17 dis-
tricts, extra efforts may be needed to achieve the same goal. Some of the challenges could
be low coverage in some communities, high baseline endemicity, programme logistical
challenges etc. The required average rounds of MDA needed to reach mf prevalence < 1%
was 11, higher than that proposed by the Global Filariasis Elimination Programme. This
article is relevant to LF control programmes in assessing the impact of MDA. It is impor-
tant for programmes to monitor infections especially within communities where mf prev-
alence is still above the 1% threshold to ensure that the WHO 2020 target is achieved.
Introduction
Lymphatic filariasis (LF), commonly known as elephantiasis, is a debilitating and disfiguring
tropical disease caused by lymphatic-dwelling filarial parasites Wuchereria bancrofti, Brugia
malayi and Brugia timori. The disease is transmitted by different species of mosquitoes
depending on the geographical location, including Culex, Anopheles and Aedes species. About
90% of the worldwide cases are caused by W. bancrofti and 10% caused by B. malayi and B.
timori. Based on re-assessment of the global prevalence and distribution of LF [1], more than
120 million people were found to be infected and 40 million disfigured and incapacitated in
the year 2000 [2]. In the same year, the Global Programme to Eliminate Lymphatic Filariasis
(GPELF) was established, aiming to eliminate the disease as a public health problem by 2020
through annual mass drug administration (MDA) with albendazole in combination with
diethylcarbamazine citrate (DEC) or ivermectin to all individuals at risk [3].
By the end of 2016, 20 out of 73 countries originally listed by the World Health Organiza-
tion (WHO) as being endemic for LF have stopped interventions after passing the first trans-
mission assessment survey and are conducting surveillance to validate elimination as a public
health problem. Additional 30 countries have delivered MDA at least once in all endemic areas
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and are also on track to achieve the 2020 target [4]. While many have passed the TAS, there are
also reports of failure [5] and of ongoing transmission in spite of passing the TAS [5–7].
A national survey carried out in Ghana in 1994 showed that the microfilaraemia prevalence
varied from 0–20% between regions [8]. In the highly-endemic Kassena Nankana district
(Upper East Region of Ghana), the prevalence of hydrocele was 30.8% and elephantiasis of
the leg was 3.8% in the population aged 10 years and above [9,10]; 12% of extended families
reported to have at least one family member with elephantiasis of the leg [10]. The extensive
mapping of endemic communities [11] provided a database on areas in Ghana and neighbor-
ing countries that needed more efforts to eliminate the disease.
The LF elimination programme in Ghana started in 2000 and gradually scaled up over the
years and by 2006 all endemic districts were covered. The implementation and outcomes by
district were described in two recent papers [12,13]. By 2016, 81 of 98 initially endemic dis-
tricts had reached an microfilaria (mf) prevalence <1%, had passed TAS survey and stopped
MDA, while the remaining districts still had mf prevalence >1% [13] in spite of at least 10
years of MDA. The required duration of MDA turned out to be longer than the anticipated
5–6 years, which might be due to relatively high baseline mf prevalence levels. There were no
major differences with other districts in reported coverage of MDA or long-lasting insecticide
treated bednets [13].
Expected trends in infection during MDA will depend on multiple factors, including local
baseline endemicity (depending on local transmission conditions) and the achieved coverage
and compliance with MDA [7,14–16]. We aim to assess the impact of MDA on mf prevalence
levels and to review progress towards LF elimination in Ghana from 2000–2016. For this pur-
pose, we analyze community-level data from mf prevalence surveys and transmission assess-
ment surveys (TAS) from sentinel and spot-check sites for all endemic districts in Ghana.
Methods
Ghana Filariasis Elimination Programme
The Ghana Filariasis Elimination Programme (GFEP) was established in June 2000 following
the establishment of the Global Programme to Eliminate Lymphatic Filaraisis. Mapping of
communities started in 2000 using the 50-km sample grid, rapid assessment procedure for
antigenaemia in sample villages and spatial analysis to plot prevalence contours from 2000 to
2001 [11,17]. Forty nine districts out of 110 were initially identified as endemic and therefore
selected for implementation of MDA. The GFEP implementation, programme outcomes, chal-
lenges and districts re-demarcation have been described in Biritwum et al. (2017a). Based on
current demarcation, 98/216 districts (45%) are endemic with LF in Ghana.
The treatment implemented in Ghana was the combination of ivermectin (150 μg/kg) and
albendazole (400 mg) given annually by the community-directed treatment approach [18] and
implemented at the district level. MDA usually took place between March and June in all
endemic communities across the country. Individuals eligible for treatment were those aged
�5 years (excluding pregnant women, lactating mothers and the sick), and selection was solely
based on height (�90 cm) for those whose ages were not known. MDAs usually lasted for
about 1–2 weeks per community. Individual treatment information (whether treated, absent,
pregnant, sick, etc) was recorded in the community treatment book and summarized into
treatment records by the Ghana Health Services (GHS). Community-level treatment coverage
data (number treated out of total population at risk) across the country were reviewed and
summarized by the GHS. For the purpose of this study, summary reports were reviewed.
There was no treatment offered in 2011 due to logistic and funding challenges; 2009 and
2012 treatment data were not available.
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Monitoring and evaluation
Parasitological surveys. Parasitology data were collected by the GHS in programmatic
yearly surveys (2000–2014) in selected endemic communities. In 2000, baseline mf surveys
were carried out in 24 purposefully selected endemic communities (based on known high
endemicity and population stability) [19,20] from the 8 districts where MDA was first initiated.
From 2001–2004, baseline mf surveys were done in sentinel sites of remaining districts, as
MDA was being extended into these districts. Subsequently, the previously selected sentinel
sites per district were repeatedly surveyed to monitor progress to elimination (usually once
every 2 or 3 years, but sometimes the interval was much longer due to financial constrains).
Additional surveys were done in spot-check sites (same characteristics as sentinel) that were
surveyed only once and often selected randomly from the same district where sentinel site is
located to cross check the MDA performance in that district.
The mf surveys were usually done at the end of the year between November and December
(before MDA treatment was done the following year between March-July). The target number
of persons for sampling increased over time based on WHO guidelines; between 2000–2002
the target was 100 persons per community, between 2003–2009 it was 500 persons, and after
2009 it was 1000–1500 persons. The method of sampling for the community survey was conve-
nient sampling, where participants who presented themselves were sampled from a central
location until the minimum requirements for WHO was met. The surveys were usually pre-
ceded by a community gathering or announcement by the team informing members of
the community to converge for the night blood collection (9pm − 2am). The eligible were
verbally consenting individuals (parent consented for their children) aged� 5years or with
height� 90cm height for those whose ages were not known, including pregnant women and
lactating mothers (There was no effort to seek balance of age, sex or any other factor of the
selected participants). Blood was sampled from these individuals by finger pricking (middle or
forth finger) and a volume of 60μl taken for thick blood smear test (2000–2009) [21]. In later
years (2010–2014), the volume of blood sampled was increased to 100μl and the microfilariae
were counted using a regular microscope with a rafter counting chamber [22], by trained GHS
laboratory technicians.
Transmission assessment surveys. The transmission assessment surveys (TAS) in Ghana
followed the WHO guidelines, using antigenaemia prevalence in children aged 6–7 years as
indicator of active transmission of LF [23]. TAS has a different sampling system and a different
target population than a full mf survey. In Ghana, the elimination programme used a district
as an implementation unit (IU) for MDA. The evaluation unit (EU) to assess progress of pro-
gramme may also be a district or a cluster of districts with a population not more than 2 mil-
lion. In some of the cities where the district population was more than 2 million, the district
was divided into different EUs. An EU qualified to be assessed after achieving treatment cover-
age of�65% for 5 years and also recording mf prevalence of<1%. Those EUs who met the cri-
teria were selected for the TAS. The TAS involved sampling of children 6–7 years in primary
schools within the EU after written consent from their parents. The schools to be surveyed, the
number of children to be tested and the critical cut-off point (maximum number of positives
to fail TAS) were estimated using a survey sample builder software recommended by WHO
[24]. A volume of 100 μl blood was taken from the children by finger pricking and test done
using immunochromatographic card test (ICT) [25]. The EUs passed TAS if the number of
positive children was less than or equal to the critical cut-off and MDA was stopped after pass-
ing TAS-1. Subsequently, two more TAS surveys (TAS-2 & TAS-3) are done after 2–3 years
and 5 years respectively before elimination of LF as a public health problem is said to be
achieved. No mf surveys continued in any community within EUs that passed TAS-1. During
Progress towards lymphatic filariasis elimination in 430 communities in Ghana
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007115 August 9, 2019 4 / 15
TAS-1, the EU with number of positive children above the critical cut-off point, failed the TAS
and continued MDA for 2–3 years. In such EUs, a community survey was required to achieve
an mf prevalence of<1% before TAS-1 was repeated [13].
Data collation and analysis
The longitudinal parasitological and treatment data from 2000–2014 were collated along with
background information from the GHS and updates on TAS results until early 2016. Parasito-
logical data comprised of number examined and number that were microfilarial positive in
each community. Community mf prevalence was estimated as the number of microfilarial pos-
itives as a percentage of number examined in the community. Mf prevalence (for the districts
or country) were calculated by estimating the percentage of total positive / total examined of
communities included in the sampling for the district or country. Similarly, the treatment cov-
erage (for the districts or country) were calculated by estimating the percentage of total treated
/ total population of communities included in the sampling for the district or country. We
present data on community, district and country level.
Data limitations and special situations. We only consider mf prevalence data in our
analysis of community-level trends in infection prevalence. No mf prevalence data were avail-
able for 2001 and data for 2002 were limited to few sites, as all community surveys in 2001 and
part of the survey in 2002 only used ICT antigenaemia tests. For 3 districts in 2003 (with 2
communities surveyed per district) and all districts in 2005 (with 3–4 communities surveyed
per district) mf prevalence was not reported for each community separately, and we only
know the overall mf prevalence—aggregated over the surveyed communities. These aggregated
data points were included in combined trends (averages) for all communities, but were not
matched to community specific data for analysis for time trend analysis. There were no mf
surveys carried out in 2006. Mf prevalence data in 2008 and 2010 were excluded from trends
and analysis since communities sampled in these years were not randomly selected (mf data
from individuals closely related to school children who were positive using ICT during school
surveys).
Ethics statement
Ethical clearance was obtained from the Ghana Health Service Ethical Review Committee (ID
NO: GHS-ERC-10/0/06) and the Liverpool School of Tropical Medicine’s Research Ethics
Committee’s Research Protocol Approval (06.47). The study obtained oral informed consent
from adult participants while parents and guardians orally consented for their children and
wards to be part of this study. Due to the programmatic nature of the study with regular MDA
and mf surveys done in many sites, participants in these communities were aware of the pro-
gram. Given that the communities were mainly rural with study participants having minimal
or no education and being suspicious of signing documents they did not well understand, oral
consent was applied and noted as part of questionnaires during the surveys. Oral informed
consent was approved by the Ghana Health Service and Liverpool School of Tropical Medi-
cine’s ethical review committees.
Results
Overview of MDA implementation in Ghana
MDA started between 2000 and 2001 in 10/98 districts selected from the northern and coastal
regions of Ghana. In 2002, 17 more districts were enrolled onto the MDA programme and in
2003, 2004, 2005 and 2006 a number of 27, 16, 25 and 3 more districts were enrolled onto the
Progress towards lymphatic filariasis elimination in 430 communities in Ghana
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007115 August 9, 2019 5 / 15
MDA programme respectively (Figs 1 and 2). All communities in each district were expected
to be treated in the same year MDA started, thus geographical coverage within a district was
expected to be 100%.
Reported coverage of MDA by calendar year in Ghana
The median reported treatment coverage in treated districts of Ghana seemed to be constant
over time, around 77–80% between 2000–2010, and the interquartile range and distribution
of outliers were also similar over time (Fig 3). Although mean reported coverage per year seem
to be high, there are large differences between communities. Community-level coverage esti-
mates varied from 10 to 120%, with at least 7952/41265 (19.3%) surveys having a coverage
under 65% and 198/41265 (0.5%) surveys over 100%, indicating wrong denominators.
TAS was done in 5 districts in 2010, and all passed. Another 65, 9 and 2 districts had their
first TAS in 2014, 2015 and early 2016, respectively and all passed. By the end of 2016, 81 out
of the 98 endemic districts had passed the TAS in Ghana and had stopped MDA (Figs 1 and
2). 17 are left, of whom 4, 3, 8, 1 and 1 district have done 11, 12, 14, 15 and 16 rounds of MDA,
Fig 1. Progress of MDA implementation in Ghana by district. NB: In the year 2011, there was no treatment due to
some logistical challenges. The maps give an overview of the treatment progression to cover all the endemic districts in
Ghana.
https://doi.org/10.1371/journal.pntd.0007115.g001
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respectively (see S2 Table, supplementary data for details). The average number of treatment
rounds in districts that stopped MDA was 11 rounds, varying from 8–14. TAS-2 was per-
formed in 69 districts in 2012 or 2015, and all districts passed. Details of the TAS surveillance
in Ghana are given in S2 Table, supplementary data.
Trends in Mf prevalence
Mf prevalence data were available from 613 community mf surveys (datapoints), carried out
between 2000 to 2014 in 430 communities (292 sentinel sites; 138 spot-check sites) in 78 out of
the 98 endemic districts (within 8/10 regions of Ghana). Twenty districts were not represented
in our compiled database, either because only antigenaemia data or TAS data were available or
because no surveys had been done after re-demarcation of districts. 352 communities were
measured only once and 78 measured multiple times (sampled between 2–6 times). Out of
Fig 2. Duration of MDA by district in Ghana. A) Period of MDA by each district in order of start year. Each
horizontal line represents a district. Bars with a dashed section on the right-hand side represent districts where MDA is
still ongoing after 2016 with unknown end year. See supplementary S2 Table for more details. B) Frequency
distribution of the number of years of treatments provided by district through 2016, presented separately for districts
that had stopped MDA by 2016 and those with still ongoing MDA.
https://doi.org/10.1371/journal.pntd.0007115.g002
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those measured multiple times, 35 communities also had data including baseline. Most of the
single time point surveys were observed after 2007 (Fig 4A). Overall, the total number of indi-
viduals sampled per year ranged between 1,784–19,268.
Baseline mf prevalence
Baseline parasitological surveys were carried out in the years 2000–2004, before the start of
MDA, examining 7,882 individuals from 53/430 communities within 21/98 districts. The
number of individuals examined per community at baseline ranged between 52–441 (mean
137, median 112). The average mf prevalence at baseline was 8.7% (range 0–45.7%) with the
highest recorded in Gyahadze located in the central region of Ghana (See supplementary S1
Table).
Trends in mf prevalence over time (2000–2014)
Community-level mf prevalence data are presented by calendar year (Fig 4A). The impact of
MDA on mf prevalence cannot clearly be seen from this figure, due to the differences between
communities in start year of MDA. In Fig 4B, therefore, the same data are presented by time
since first treatment, while Fig 4C presents these data in boxplots to better visualize the distri-
bution of the observed community-level mf prevalence. The variation in baseline prevalence
was large (ranged between 0–45.7% with interquartile range of 0.46–22.9%). The mean and
median mf prevalence in surveyed communities declined strongly with increasing duration of
MDA. Although 6–7 years after the onset of MDA the median prevalence had fallen below 1%,
the variation was still large (range = 0–20.8%; interquartile range = 0–1.5%) between commu-
nities and many communities still had mf prevalence levels above 5% (Fig 4C). Yet, we still see
a continued decline in the maximum observed prevalence levels with increasing duration of
Fig 3. Reported treatment coverage in treated communities in Ghana. The box at each time point represents the
interquartile range of coverage and the thick horizontal lines across each box represent the median coverage. The
bullets outside each box (above or below) represent the outliers and are calculated as 1.5 times the interquartile range
above or below the ends of the box (25th and 75th percentile). The vertical lines (whiskers) extend to the first value
(coverage) before the outlier cut-off and where there are no outliers, they represent the minimum and maximum
coverage at each time point. The numbers in the boxes are the total number of communities treated at each time point.
There was no treatment offered in 2011 due to some challenges; 2009 and 2012 treatment data not available.
https://doi.org/10.1371/journal.pntd.0007115.g003
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Fig 4. Observed lymphatic filariasis mf prevalence in sentinel and spot-check sites in Ghana, measured in the
population aged 5 and above, for the period 2000–2014. A) Data presented by calendar year. Multiple observations
from the same community are connected through thin grey lines. Observations from communities surveyed only once
are highlighted in brown. Observations presenting aggregated prevalence over multiple communities are displayed in
blue (in 2003 and 2005). Dashed lines represent the average prevalence from all surveyed communities at each time
point. Bullets at the same time point have been jittered to avoid overlapping of points at the same position; these do not
represent time in months. B) As panel A but with time since first treatment on the horizontal axis. C) As B, but with
data summarized in boxplots. The box at each time post treatment represents the interquartile range of mf prevalence
Progress towards lymphatic filariasis elimination in 430 communities in Ghana
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MDA. In most communities with multiple measurement the mf prevalence steadily decreased
over time, but 12 out of 78 (15%) communities had at least once an increase between 2 time
points (Fig 4A & 4B). In the 2013 and 2014 surveys, 7 and 10 communities respectively were
identified with mf prevalence still above 1% (maximum 5.6%). Fifteen out of these 17 commu-
nities with threshold above 1% are within 13 districts (out of 17 districts) where MDA was still
ongoing by 2016.
In 34 districts, one or more communities were surveyed at least twice during the period of
MDA. Data for these districts are shown in supplementary file S1 Fig. When community data
were aggregated at district level, there was a general decrease in average mf prevalence over
time to approach zero in most districts (S1 Fig, red line). In 4 districts (Bongo, Jirapa, Lambus-
sie-K and Lawra) there were slight increases in mf prevalence after baseline before decreasing
steadily. Almost all the districts we assessed, apart from two (Lawra and Wa-West), showed mf
prevalence less than 5% after 6 years of MDA (S1 Fig, supplementary data). In 31 out of these
34 districts (91%), mf prevalence eventually fell below <1% after 6–14 rounds of treatment;
this was not the case in three districts (Bole, Jirapa and Wa-West) where the mf prevalence was
still�1% in 2013 or 2014 and MDA still ongoing by 2016. 51 out of the 78 examined districts/
IUs (65%) needed more than 6 rounds of MDA to reach mf prevalence of<1%. There was a
moderately positive correlation (correlation coefficient = + 0.5) between baseline mf preva-
lence versus years of MDA required for each district (limited to districts that have stopped
MDA) [S2 Fig, supplementary data].
Discussion
Ghana has made good progress towards elimination since the start of its elimination pro-
gramme in 2000. The baseline mf prevalence in sentinel sites was 8.7% on average, ranging
from 0 to 45.7%. The mf prevalence declined steeply during the first few years after starting
MDA in communities, followed by a more gradual decline thereafter (Fig 4A). Surveys per-
formed after 6–7 rounds of MDA showed high variation between communities in mf preva-
lence, with the mf prevalence often exceeding 1% or even 5% (Fig 4B & 4C). By the end of
2016, 81 out of 98 endemic districts had stopped mass drug administration (MDA) after an
average of 11 rounds (range 8–14) and treatment ongoing in 17 districts.
We have created a unique longitudinal database on the long-term impact of MDA for lym-
phatic filariasis (LF) elimination in Ghana, containing data from 430 sentinel and spot-check
sites. There are at least 12 countries that have reported longitudinal trend data on at least 3
microfilaria (mf) prevalence surveys of LF after at least 3 rounds of MDA, of whom 5 in Africa:
Tanzania, Kenya, Nigeria, Egypt and Mali [26–31]. These African studies have reported the
impact of 4–10 rounds of MDA on antigenaemia/mf prevalence within 4–20 sentinel/study
sites where about 50–2000 participants were tested per year. Since we have more data (15 years
MDA, 430 communities, 1,784–19,268 participants), this gives us more insight into the impact
of MDA on mf prevalence, the dynamics involved over a period of time and the variability in
outcomes between sites.
At country-level we observed a huge variation in baseline endemicity level and trends
towards reaching the threshold below 1% (Fig 4A & 4B). The mean and median mf prevalence
in�5 years and the thick horizontal lines across each box represent the median mf prevalence. The bullets outside
each box (above or below) represent the outliers and are defined as 1.5 times the interquartile range above or below the
ends of the box (25th and 75th percentile). The vertical lines (whiskers) extend to the first value (mf prevalence) before
the outlier cut-off and where there are no outliers, they represent the minimum and maximum mf prevalence at each
time post treatment. The numbers in the boxes are the total number of communities examined at each time post
treatment.
https://doi.org/10.1371/journal.pntd.0007115.g004
Progress towards lymphatic filariasis elimination in 430 communities in Ghana
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007115 August 9, 2019 10 / 15
in surveyed communities declined strongly with increasing duration of MDA. The small
increase in median prevalence observed 1 year after the onset of sampling is a selection effect
and does not indicate a lack of impact, because surveys were only done in districts with a rela-
tively high baseline mf prevalence. The number of districts and communities surveyed declines
over time, because districts that have stopped MDA were no longer included in surveys. In
addition, surveys were selectively performed in communities in districts with low reported
coverage or relatively high prevalence in previous surveys. For these reasons, trends in mean
and median mf prevalence of surveyed villages during later stages of the control are difficult to
interpret. Patterns became clearer with less variation within districts when we plotted and ana-
lyzed data by districts (S1 Fig). For some districts only few observations were available, espe-
cially in districts with relatively low baseline prevalence, where mf prevalence was relatively
rapidly reduced below 1%, obviating the need for further surveys.
When GPELF was initiated, it was expected that 5 or 6 rounds of MDA with good cover-
age–�65% would be sufficient to eliminate LF as a public health problem [3,32]. Although few
countries were indeed able to reach the goal within the 5–6 years of MDA [2], the required
treatment duration in Ghana was always longer, often considerably longer. This experience
can help other African countries with planning their interventions. Previous modelling studies
already suggested that 5–6 rounds of MDA would not be enough in case of low coverage and/
or high baseline endemicity [7,14–16], and the same factors may explain why the required
treatment duration in some Ghanaian districts is much longer than in others [13]. In districts
with relatively high baseline mf prevalence, sometimes many rounds of MDA were needed to
ensure that mf prevalence reach below 1%. Our data shows a moderately positive correlation
between baseline mf prevalence versus years of MDA required for each district (S2 Fig). How-
ever, the decision to stop MDA was at the district level (IU), and therefore also influenced by
other communities. Additionally, the programme in Ghana did not evaluate yearly to assess
whether treatment could be stopped. These factors could have influenced the timelines
somehow.
Our data confirm the importance of baseline endemicity for the required treatment dura-
tion, but the role of coverage was more difficult to proof. Reported coverage data at commu-
nity level were collated for all endemic districts of Ghana (Fig 3). Although the reported
coverage was good for the majority of communities, coverage levels <50% are also frequently
encountered. However, such data are notoriously unreliable, as also becomes clear from the
frequent occurrence of reported coverage levels >100% and hence difficult to interpret [33].
Low coverage is problematic, particularly if it is sustained over multiple treatment rounds. We
could not assess the importance of this phenomenon in our data, as it appeared difficult to
match coverage data from subsequent years at community level and to match them to the mf
prevalence data.
The high variation in mf prevalence after a given number of treatment rounds within dis-
tricts, as observed in Ghana (this study) and elsewhere [5–7] complicates decision making. If
communities with high residual mf prevalence are by chance not included in surveys, MDA
may be stopped prematurely with danger of resurgence [5]. This could be prevented by target-
ing pre-TAS surveys to communities at high risk of residual transmission. High risk may
occur due to programmatic or demographic factors [12], including migration during treat-
ment period, treatment fatigue, high numbers of middle aged women (child bearing age;
majority not taking drug due to pregnancy) etc.
Other local factors contributing to transmission may be high biting rate of the mosquitoes
and behavior of residents that influence exposure to mosquito bites [16,34]. The vectorial
capacities of different LF vector species influence the ability to interrupt transmission using
MDA in different settings [35]. In Ghana, for example, high biting rates of the major vector
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An. gambiae and initial infection prevalence, coupled with high densities of other vector spe-
cies such as An. melas and Mansonia have explained the ongoing LF transmission in some hot-
spot communities [36]. The impact of bednets on mf prevalence cannot be overruled. Bednet
coverage in Ghana was <25% throughout the country until 2005. This varied between 25%
− 50% in 2005–2010; and further increased after 2010 [37]. Bednet coverage leads to a gradual
reduction in mf prevalence, due to the long lifespan of worms, whereas immediate strong
declines results from MDA. Trends in mf prevalence are therefore mostly defined by MDA
and not by bednet usage. Bednets however, may be crucial in the end stage to prevent resur-
gence of infection after stopping MDA.
Although TAS has been designed to cover a larger geographical area with the hope that
pockets with residual transmission would be identified in TAS surveys, it is unclear whether
TAS is sufficiently sensitive to pick up such pockets. This is because not all communities
within the evaluation unit (district) are sampled, furthermore, some have reported transmis-
sion ongoing in spite of passing TAS [5,6]. Thus, the validity of TAS for longer-term post-
MDA surveillance requires further investigation [38]. We could not assess this in the current
study, as most districts are usually not resurveyed shortly after stopping MDA.
Our data had some limitations. Firstly, we only considered mf data, as antigenaemia preva-
lence data were not always collected. Survey sites (apart from spot-check sites) were not ran-
domly chosen, but rather based on previous results and location, and most mf sites have been
surveyed only once. The low number of persons sampled combined with less sensitive mf tests
in early years makes the mf prevalence observed in early years less reliable (wide 95% CI, data
for baseline shown in supplementary data, S1 Table). Also, the selection of participants for
night blood collection in each community was also not random since some households were
more likely to attend than others. This is particularly problematic if those not participating in
surveys are also more likely not to participate in MDA, resulting in biased and possibly flat-
tered mf prevalence estimates. The mf prevalence data did not provide details such as age and
sex, therefore the depth of analysis was limited.
Conclusions and recommendations
The Ghana Filariasis Elimination programme has had large impact, reducing mf prevalence
<1% in 81/98 endemic districts. The remaining 17 districts still need MDA but also seem to be
approaching this target. There was variation in the required treatment rounds between and
within districts. Stopping MDA must be done with caution, taking into account the risk that
communities with residual transmission remain which could present a source for the resur-
gence of infection after stopping MDA. Monitoring at the community level is required to be
maintained to sustain the gains that have already been made towards elimination of LF in
Ghana.
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